APA (7th ed.) Citation

Alten, R., Burmester, G. R., Matucci-Cerinic, M., Salmon, J., Lopez-Romero, P., Fakhouri, W., . . . Fautrel, B. (2023). The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: A 6-Month Interim Analysis. Rheumatology & Therapy, 10(1), 73. https://doi.org/10.1007/s40744-022-00500-6

Chicago Style (17th ed.) Citation

Alten, Rieke, et al. "The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: A 6-Month Interim Analysis." Rheumatology & Therapy 10, no. 1 (2023): 73. https://doi.org/10.1007/s40744-022-00500-6.

MLA (9th ed.) Citation

Alten, Rieke, et al. "The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: A 6-Month Interim Analysis." Rheumatology & Therapy, vol. 10, no. 1, 2023, p. 73, https://doi.org/10.1007/s40744-022-00500-6.